The 2019-nCoV Neutralization ELISA Kit
With more than 111 million cases globally and more than 2 million deaths, the current COVID-19 pandemic remains one of the most urgent public health emergencies.
In order to inhibit the spread of the virus while continuing to develop rapid therapeutics, scientists must not only investigate the virus itself but must also be able to comprehend the human body’s immune responses to this novel virus.
This understanding of immunity helps scientists to develop improved diagnostic kits, as well as effective therapies such as vaccines and nanobody therapeutics.
Neutralizing antibodies (Nabs) are an important set of immunoglobulins (IgGs). Nabs are a key part of the body’s adaptive immune response against pathogens, and these antibodies bind to the key epitopes rendering them unable to bind to cell receptors and enter cells.
SignalChem 2019-nCoV High Sensitivity S1 Protein ELISA Kit
The spread of the Severe Acute Respiratory Syndrome-related novel coronavirus SARS-CoV-2 led to the global pandemic of the respiratory disease (COVID-19) in 2020. Researchers across the globe are working to develop potential treatments, vaccines and drugs to combat the new coronavirus and 2019-nCoV acute respiratory disease.
RT-PCR is the earliest method that can be applied in the detection of pathogens, and a real-time fluorescent RT-PCR positive result is widely utilized as a means of confirming coronavirus infection.
Diagnosis via nucleic acid detection is prone to a number of problems such as false negatives, long detection times and strict requirements in terms of equipment and lab personnel expertise. Additional CT scans and other clinical symptom indicators are often required for an accurate diagnosis of COVID-19.
The Anti 2019-nCoV Spike Protein Llama Heavy-Chain Antibody
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) or 2019-nCoV is a virus that triggers an ongoing outbreak of the lower respiratory tract disease known as coronavirus disease 2019 (COVID-19).
There have been over 111 million cases worldwide thus far, and the ongoing pandemic has led to an enormous amount of disruption in public health and safety.
The SARS-CoV-2 virus enters host cells by binding to the ACE2 receptor enzyme, because of this, effectively targeting the RBD-ACE2 interaction has the potential to open therapeutic avenues in the ongoing fight against the virus.
Conventional antibodies or immunoglobulins (IgG) are used as a means of therapeutic intervention, but a further subclass of IgGs from the camelid family with an unpaired heavy-chain domain has been found to facilitate competitive blocking of RBD-ACE2 binding.
AAFP Highlights Primary Care in Rescue Package Needs
Pay Parity, Workforce Priorities Among Key Academy Asks
February 15, 2021, 3:15 pm News Staff In a
Feb. 10 letter to congressional committee leaders, the AAFP called for legislative action to bolster primary care and improve Americans’ access to it. The recommended measures, wrote the Academy, are in close alignment with the Biden administration’s COVID-19 stimulus and recovery plan.
“The American Rescue Plan calls for significant investment in COVID-19 vaccinations, testing and treatments. Primary care is a critical gateway to all of these,” the letter said. “Additionally, primary care physicians are among the most trusted advisers for vaccine decisions and will be
Conference Spotlights New Research to Benefit Primary Care
Conference Spotlights New Research to Benefit Primary Care
Febuary 4, 2021, 3:24 pm News Staff The talents of family medicine researchers from across the United States and elsewhere were on full display at the 48th annual meeting of the North American Primary Care Research Group, held virtually late last year.
The meeting of more than 850 researchers gave attendees the opportunity to participate in more than 700 forums, oral presentations, poster presentations and workshops. Sessions were offered on demand or via livestream and included dozens of topics of interest to family physicians and other primary care clinicians.